Hovione Completes $100 Million Investment to Expand Operations at US Manufacturing Site
Hovione has completed a $100 million investment to double spray-drying capacity and expand its East Windsor, New Jersey site, positioning the facility to meet growing US demand for advanced drug formulation and manufacturing services with GMP operations starting in 2026.
Hovione, a fully-integrated global CDMO, announced the completion of an initial multi-million-dollar investment cycle to expand its manufacturing site in East Windsor, New Jersey. Upon completion, the site will cover more than 200,000 square feet, integrating the latest technologies within sustainably designed facilities. The initiative advances Hovione’s long-term strategy to grow its US operations and enhance its integrated drug substance, drug product intermediate, and drug product capabilities.
The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for the production of amorphous solid dispersions (ASDs) for the company´s customers that have an interest in having a supply node in North America. This investment more than doubles Hovione’s spray drying capacity in the United States, expanding capabilities for ASD development and commercial manufacturing. Construction is already underway at the Hovione New Jersey site, with GMP operations planned to start in the second quarter of 2026.
“Since launching our New Jersey operations in 2002, Hovione has been one of the longest-established European CDMOs in the United States,” said Jean-Luc Herbeaux, CEO of Hovione. “This investment reinforces Hovione’s leadership in spray drying – a core technology platform where we have built extensive know-how and capabilities. By continuing to advance our platforms and expand capacity in the US, we are strengthening the foundation that enables our partners to bring complex medicines to patients more efficiently.”
Herbeaux continued, “This investment addresses growing customer demand for U.S.-based capacity and integrated solutions that shorten development timelines and reduce tech transfer complexity. By consolidating development, scale-up, and commercial manufacturing within a single quality and governance framework, we provide customers with seamless execution from drug substance to drug product.”
As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth and ensure the East Windsor site continues to meet evolving customer needs. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the next generation of pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities.
David Basile, Vice President of Technical Operations – Americas at Hovione, said, “This expansion in New Jersey marks a significant step in extending our capabilities in the US, which go far beyond machine time or equipment capacity. We are integrating our teams, specialized assets, proprietary technologies, and digital systems to deliver distinctive end-to-end ASD and continuous tableting platforms to our customers. Through our new strategic engagement model, customers can gain privileged access to innovation and assets that accelerate their programs and create long-term value.”
Hovione’s expansion in East Windsor forms part of a broader international growth plan that also includes capacity investments in Ireland and Portugal. Together, these initiatives will create a network of autonomous sites spanning the development and commercialization of APIs, drug product intermediates, and drug products, all under harmonized quality systems.
